MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
RCKT stock logo

RCKT

Rocket Pharmaceuticals, Inc.

$3.64
-0.09
 (-2.41%)
Exchange:   NASDAQ
Market Cap:   392.771M
Shares Outstanding:   2.103M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Gaurav D. Shah
Full Time Employees:  299
Address: 
9 Cedarbrook Drive
Cranbury
NJ
8512
US
Website:  https://rocketpharma.com
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones EnergΓ©ticas, Medioambientales y TecnolΓ³gicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Click to read more…

Revenue Segmentation

πŸ”’ You are currently logged out

Login

EPS

πŸ”’ You are currently logged out

Login
View full analyst estimates

Earnings Call

πŸ”’ You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

πŸ”’ You are currently logged out

Login

Current Key Metrics

πŸ”’ You are currently logged out

Login

Forward P/E Ratios

πŸ”’ You are currently logged out

Login

SWOT Analysis

πŸ”’ You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

πŸ”’ Premium Feature

Log in to access the RCKT Intrinsic Value Calculator

πŸ”‘ Log In
πŸ“ Sign Up Free

Get comprehensive stock analysis with premium features

πŸ”’ You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news

06-08-2025 16:00
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
10-08-2025 11:38
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Secur
08-08-2025 14:16
DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025
07-08-2025 14:32
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
06-08-2025 17:44
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
06-08-2025 10:00
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – RCKT